Moleculin (MBRX) CFO Jonathan P. Foster Buys Stock

What Happened Jonathan P. Foster, Chief Financial Officer of Moleculin Biotech, acquired 293,333 shares of common stock and Series I warrants to purchase 879,999 additional shares in a public offering. The combined purchase price was $0.75 per share (each share came with three accompanying warrants), implying roughly $220,000 cash paid for the common shares; the warrants provide additional upside if exercised later. This was a purchase (a generally bullish action relative to a sale).

Key Details

• Transaction date: August 3, 2026; filing date: August 5, 2026 (appears timely).
• Consideration: $0.75 per share with three Series I warrants per share (total warrants = 879,999).
• Securities acquired: 293,333 common shares (direct) and warrants to purchase 879,999 common shares (derivative).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: F1 — the shares and three accompanying warrants per share were acquired in a public offering at the combined price noted above.
• Transaction code: P (purchase); derivative component reported separately.

Context The derivative portion consists of Series I warrants (3 warrants per share purchased) that give the holder the right to buy additional shares under the warrants’ terms (exercise price/expiration not listed in the excerpt). Because this was a cash purchase in a public offering rather than a sale or a gift, it signals an insider investment of capital into the company; the warrants add potential future upside but also require future action/payment to realize.